EU Regulatory Roundup, April 2020: MDR Delayed As EU Manages COVID-19 Crisis
Executive Summary
COVID-19 is now entirely dominating the world of medtech. It has forced the commission to delay the MDR. While the sector tries to grapple with the impact, it is also having to adjust to a healthcare market that is driven by coronavirus demands.
You may also be interested in...
EU Regulatory Roundup, March 2020: MDR Delay And Unprecedented COVID-19 Measures
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.